Antengene Announces the Approval of First-in-Class Oral XPO1 Inhibitor Selinexor in South Korea for the Treatment of Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma ...Middle East

SEOUL, South Korea and SHANGHAI and HONG KONG, Aug. 1, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class...

Read More Details
Finally We wish PressBee provided you with enough information of ( Antengene Announces the Approval of First-in-Class Oral XPO1 Inhibitor Selinexor in South Korea for the Treatment of Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma )

Also on site :

• Disney World Announces Opening Date for First Nighttime Parade in Nearly a Decade
• 'Law & Order' Fans Stunned by 'Girls Night Out' Photos of Mariska Hargitay and Kelli Giddish
• ‘Not really leaving’: Trump bids goodbye to Elon Musk at White House event